Democrats dig in on health care as threat of government shutdown looms

Democrats dig in on health care as threat of government shutdown looms


U.S. Senate Minority Leader Chuck Schumer (D-NY) speaks to reporters as Senate Democratic leaders hold a press conference following their weekly policy lunch on Capitol Hill in Washington, D.C., U.S., Sept. 9, 2025.

Elizabeth Frantz | Reuters

Congressional Democrats are zeroing in on health care as a key sticking point in negotiations with the threat of a government shutdown looming.

Senate Democratic Leader Chuck Schumer and House Democratic Leader Hakeem Jeffries, both of New York, have said that they will not support GOP-backed legislation to keep the government funded unless it includes certain health-care provisions, setting up a bitter policy fight with GOP lawmakers that could trigger a shutdown.

“We have made clear that under no circumstances will we support a partisan Republican spending bill that continues to rip away health care from the American people,” Jeffries said on the House floor this week.

With funding on the brink, congressional Democrats are demanding that any legislation that would avert a shutdown include an extension of the Affordable Care Act tax credits, which are set to expire at the end of this year unless Congress intervenes.

If the tax credits disappear, average premiums could soar by about 75%, according to KFF, a nonpartisan health policy research group.

The vast majority of Americans with a health plan from the ACA marketplace had a premium tax credit in 2025, according to KFF, meaning their elimination would have widespread consequences.

Democrats have also repeatedly criticized the cuts to Medicaid that were part of the “One, Big Beautiful Bill,” and they want Republicans to reverse them.

Read more CNBC politics coverage

With Democrats appearing to hold firm, their new hard line will complicate negotiations ahead of Sept. 30, which is when government funding is currently set to expire.

A unified House Republican conference could pass legislation without Democratic support, but Senate Republicans need some Democratic support, given their razor-thin majority.

In March, Schumer joined Republicans to avert a government shutdown, but his move drew sharp criticism from his party.

This time, with an eye on the 2026 midterm elections, Schumer and his Democratic colleagues have signaled that they will not support government funding legislation that does not include the key concessions.

But Republicans, for their part, also appear unlikely to budge on the Democratic lawmakers’ requests.

President Donald Trump dismissed Democrats’ demands, telling Fox News this week that “there is something wrong with them.”

“If you gave them every dream right now … they want to give away money to this or that and destroy the country. If you gave them every dream, they would not vote for it,” Trump said on “Fox and Friends.”

Senate Majority Leader John Thune, R-S.D., also accused Democrats of “clamoring” for a government shutdown.

“They want a fight with the Trump administration,” Thune told Punchbowl News’ “Fly Out Day.”

“But they don’t have a good reason to do it. And I don’t intend to give them a good reason to do it,” he continued.

With time ticking, lawmakers are likely to pursue a stopgap measure to keep funding stable at federal agencies.

But even reaching that temporary solution will be an uphill battle.



Source

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
Health

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech

A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., Sept. 30, 2025. Mike Blake | Reuters Pfizer on Monday said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker’s attempt to outbid Pfizer to acquire the obesity biotech is […]

Read More
Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More